VXL Stock Overview
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxil Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.035 |
| 52 Week Low | CA$0.01 |
| Beta | -3.58 |
| 1 Month Change | 50.00% |
| 3 Month Change | n/a |
| 1 Year Change | -25.00% |
| 3 Year Change | -88.00% |
| 5 Year Change | -57.14% |
| Change since IPO | -93.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| VXL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 50.0% | -6.4% | -2.1% |
| 1Y | -25.0% | -35.6% | 3.6% |
Return vs Industry: VXL exceeded the Canadian Biotechs industry which returned -35.6% over the past year.
Return vs Market: VXL underperformed the Canadian Market which returned 3.6% over the past year.
Price Volatility
| VXL volatility | |
|---|---|
| VXL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: VXL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VXL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Goren | www.vaxil-bio.com |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment.
Vaxil Bio Ltd. Fundamentals Summary
| VXL fundamental statistics | |
|---|---|
| Market cap | CA$2.05m |
| Earnings (TTM) | -CA$453.00k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs VXL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$453.00k |
| Earnings | -CA$453.00k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VXL perform over the long term?
See historical performance and comparison